All In Biotech

Drug Trial Radar · NCT04104672

A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 196 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

196

Actual

Start

Nov 6, 2019

Primary completion

Jul 21, 2026

Study completion Jul 21, 2026

Sponsor

Lead sponsor
Arcus Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Sep 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label, dose-escalation, and dose-expansion, with a gated randomization portion, study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination with zimberelimab (AB122), nab-paclitaxel and gemcitabine in participants with advanced pancreatic cancer.

Conditions

  • Advanced Pancreatic Cancer

Interventions

  • AB680Drug

    AB680 is a Cluster of Differentiation (CD)73 Inhibitor.

  • ZimberelimabDrug

    Zimberelimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1.

  • Nab-paclitaxelDrug

    Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.

  • GemcitabineDrug

    Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Treatment Emergent Adverse Events (TEAEs)Time frame: From first dose date to 90 days after the last dose (approximately 1 year)
  2. Number of Participants With Dose Limiting ToxicitiesTime frame: From First dose to day 28

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Santa Monica, California

  • Research Site

    St Louis, Missouri

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Houston, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.